-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on Abbott Laboratories, Lowers Price Target to $143

Benzinga·04/20/2026 13:23:41
Listen to the news
Barclays analyst Matt Miksic maintains Abbott Laboratories (NYSE:ABT) with a Overweight and lowers the price target from $144 to $143.